Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Leerink Partners Raises Price Target on Ironwood Pharma (IRWD) to $14; Reiterates Market Perform
August 5, 2016 9:03 AM EDTLeerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $14.00 (from $10.00), following the company's 2Q earnings report. Linzess sales grew to $150.5m, ~2% above forecasts. Underlying sales growth of +34% was driven by 29% Rx volume growth. IRWD will launch Zurampic (gout) in October 2016. Zurampic... More
Ironwood Pharma (IRWD) Misses Q2 EPS by 1c
August 4, 2016 4:19 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $54.4 million versus the consensus estimate of $55.46 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More